Pulmonary necrosis resulting from DNA vaccination against tuberculosis
- PMID: 12654841
- PMCID: PMC152079
- DOI: 10.1128/IAI.71.4.2192-2198.2003
Pulmonary necrosis resulting from DNA vaccination against tuberculosis
Abstract
The use of DNA constructs encoding mycobacterial proteins is a promising new approach to vaccination against tuberculosis. A DNA vaccine encoding the hsp60 molecule of Mycobacterium leprae has previously been shown to protect against intravenous infection of mice with Mycobacterium tuberculosis in both the prophylactic and immunotherapeutic modes. It is shown here, however, that this vaccine was not effective in a more realistic aerosol infection model or in a model of latent tuberculosis in the lungs. Moreover, when given in an immunotherapeutic model the immunized mice developed classical Koch reactions characterized by multifocal discrete regions of cellular necrosis throughout the lung granulomas. Similar and equally severe reactions were seen in mice given a vaccine with DNA coding for the Ag85 antigen of M. tuberculosis. This previously unanticipated safety problem indicates that DNA vaccines should be used with caution in individuals who may have already been exposed to tuberculosis.
Figures







Similar articles
-
Lack of protection in mice and necrotizing bronchointerstitial pneumonia with bronchiolitis in guinea pigs immunized with vaccines directed against the hsp60 molecule of Mycobacterium tuberculosis.Infect Immun. 2000 Jun;68(6):3674-9. doi: 10.1128/IAI.68.6.3674-3679.2000. Infect Immun. 2000. PMID: 10816527 Free PMC article.
-
The safety of post-exposure vaccination of mice infected with Mycobacterium tuberculosis.Vaccine. 2008 Nov 11;26(48):6092-8. doi: 10.1016/j.vaccine.2008.09.011. Epub 2008 Sep 20. Vaccine. 2008. PMID: 18809446
-
DNA vaccines against tuberculosis.Novartis Found Symp. 1998;217:239-46; discussion 246-53. doi: 10.1002/0470846526.ch18. Novartis Found Symp. 1998. PMID: 9949812
-
[Novel vaccines against M. tuberculosis].Kekkaku. 2006 Dec;81(12):745-51. Kekkaku. 2006. PMID: 17240920 Review. Japanese.
-
Immunotherapy for TB.Immunotherapy. 2012 Jun;4(6):629-47. doi: 10.2217/imt.12.52. Immunotherapy. 2012. PMID: 22788130 Review.
Cited by
-
The Pathogenesis of Tuberculosis-The Koch Phenomenon Reinstated.Pathogens. 2020 Oct 4;9(10):813. doi: 10.3390/pathogens9100813. Pathogens. 2020. PMID: 33020397 Free PMC article. Review.
-
Safety and efficacy of MVA85A, a new tuberculosis vaccine, in infants previously vaccinated with BCG: a randomised, placebo-controlled phase 2b trial.Lancet. 2013 Mar 23;381(9871):1021-8. doi: 10.1016/S0140-6736(13)60177-4. Lancet. 2013. PMID: 23391465 Free PMC article. Clinical Trial.
-
Ipr1 gene mediates innate immunity to tuberculosis.Nature. 2005 Apr 7;434(7034):767-72. doi: 10.1038/nature03419. Nature. 2005. PMID: 15815631 Free PMC article.
-
Pulmonary lymphatics are primary sites of Mycobacterium tuberculosis infection in guinea pigs infected by aerosol.Infect Immun. 2006 Sep;74(9):5397-401. doi: 10.1128/IAI.00332-06. Infect Immun. 2006. PMID: 16926435 Free PMC article.
-
Pathological role of interleukin 17 in mice subjected to repeated BCG vaccination after infection with Mycobacterium tuberculosis.J Exp Med. 2010 Aug 2;207(8):1609-16. doi: 10.1084/jem.20100265. Epub 2010 Jul 12. J Exp Med. 2010. PMID: 20624887 Free PMC article.
References
-
- Colditz, G. A., T. F. Brewer, C. S. Berkey, M. E. Wilson, E. Burdick, H. V. Fineberg, and F. Mosteller. 1994. Efficacy of BCG vaccine in the prevention of tuberculosis. Meta-analysis of the published literature. JAMA 271:698-702. - PubMed
-
- Dye, C., S. Scheele, P. Dolin, V. Pathania, M. C. Raviglione, et al. 1999. Consensus statement. Global burden of tuberculosis: estimated incidence, prevalence, and mortality by country. JAMA 282:677-686. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous